Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Visit the company website

 

Bullboard - Investor Discussion Forum Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX... see more

TSXV:VM - Post Discussion

Voyageur Pharmaceuticals Ltd > Shareholder Update
View:
Post by WarrantOfficer on Oct 05, 2021 3:53pm

Shareholder Update

Read the 4 Oct shareholder update. Lots of fluff to speak ...very short on specifics just sharing facts that we already are aware of. They have been in development talks with ThinQ for a couple of years now and were supposed to be near term revenue growth with them a long time ago. What is managements ideal of significant progress in the development program? Why are they utilizing third party materials when they submitted this picture to Resource World Magazine Sept 2019 publication:
  I am a shareholder with this compnay seeking specific honest answers from management as to the forward traction on this company. Lots of talk of ensuring shareholder value in the company, little talk about the funding required to get us there.
Comment by whitenorth72 on Oct 05, 2021 4:49pm
All good points. please inbox me if you can find any of those answers. I will do the same.
Comment by BoracayGuy on Oct 06, 2021 12:30pm
It was a good update.  Bottom line is that they're waiting on the PEA ( Prelim Economic Assessment).   Nothing can happen without it here now. It's a huge techinal document that formally sets the stage for everything (non Iodine) going fwd.   SGS Canada have dragged their feet..That's an understatement,. but it's nearing final completion now.  Note: All the ...more  
Comment by biggdogg on Oct 06, 2021 1:13pm
Agree 100%!! If you think this management team is going to pump so you can dump at $0.20-$0.30 your in the wrong stock. They are  building  a  company. Anyone with  experience is seeing that these guys walk their talk, step by  step. If you have no patience, then sell now!! LOL This is for those smart investors looking for long term growth, not flipping out at pennies ...more  
Comment by mezcal1 on Oct 18, 2021 10:55am
More great news this morning.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.VM

follow v.vm on


Voyageur Pharmaceuticals Deck 2024..

The Watchlist

Voyageur Pharmaceuticals | The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

COMPELLING
VALUE PROPOSITION

  • Only pharmaceutical company in the world that owns long-term supply of barium and iodine
  • Natural barium and iodine resources meet increasingly limited global supply and risk
  • Multi-billion-dollar global market for contrast media
  • Poised to obtain significant market share by offering high-quality, lower-cost products
  • Favorable regulatory pathway allows rapid commercialization
  • Highly experienced team has positioned the company for profitable commercial success

Contact Us

Brent Willis, CEO
Brent@Vpharma.ca

Address:
Suite 1600 Dome Tower, 333 7th Avenue S.W.
Calgary, Alberta
T2P 2Z1